Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention

Show other versions (1)

Bibliographic Details
Main Authors:	J Greenhalgh, A Bagust, A Boland, CM Saborido, N Fleeman, C McLeod, Y Dundar, R Dickson, C Proudlove, R Kolamunnage-Dona, M Fisher
Format:	Article
Language:	English
Published:	NIHR Journals Library 2010-05-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta14suppl1/05

Similar Items

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
by: J Greenhalgh, et al.
Published: (2010-05-01)

Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
by: Janette Greenhalgh, et al.
Published: (2015-04-01)

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
by: J Greenhalgh, et al.
Published: (2009-10-01)

PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM
by: O. O. Shakhmatova, et al.
Published: (2018-05-01)

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel
by: Zuzana Motovska, et al.
Published: (2009-05-01)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
by: J Greenhalgh, et al.
Published: (2011-09-01)

Rituximab for the treatment of rheumatoid arthritis
by: A Bagust, et al.
Published: (2009-09-01)

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention
by: I. N. Dyakov, et al.
Published: (2020-09-01)

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: N Fleeman, et al.
Published: (2010-05-01)

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: N Fleeman, et al.
Published: (2010-05-01)

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
by: Ahmed Amro, et al.
Published: (2019-07-01)

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
by: C McLeod, et al.
Published: (2009-01-01)

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
by: J Greenhalgh, et al.
Published: (2010-10-01)

WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
by: M. Yu. Gilyarov, et al.
Published: (2018-05-01)

P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01)

Erlotinib for the treatment of relapsed non-small cell lung cancer
by: C McLeod, et al.
Published: (2009-06-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
by: Yuri Kim, et al.
Published: (2023-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
by: Yuri Kim, et al.
Published: (2023-01-01)

Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin’s lymphoma
by: Y Dundar, et al.
Published: (2009-06-01)

Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: T Brown, et al.
Published: (2010-10-01)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
by: Shokoufeh Hajsadeghi, et al.
Published: (2016-08-01)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
by: Shokoufeh Hajsadeghi, et al.
Published: (2016-01-01)

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
by: N Fleeman, et al.
Published: (2010-01-01)

Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Drug-eluting stents: a systematic review and economic evaluation
by: R Hill, et al.
Published: (2007-11-01)

Coronary artery stents: a rapid systematic review and economic evaluation
by: R Hill, et al.
Published: (2004-09-01)

The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation
by: J Hockenhull, et al.
Published: (2008-04-01)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
by: Mustafa Yildirim, et al.
Published: (2023-08-01)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
by: Lulu Dai, et al.
Published: (2022-06-01)

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis
by: Pravesh Kumar Bundhun, et al.
Published: (2018-05-01)

The use of CytoSorb® in a prasugrel‐loaded patient undergoing emergent coronary artery bypass graft surgery
by: Erich Moresco, et al.
Published: (2023-03-01)

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation
by: C McLeod, et al.
Published: (2007-08-01)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
by: Mingxiang Wen, et al.
Published: (2020-10-01)

Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease
by: Ioanna Xanthopoulou, et al.
Published: (2018-11-01)

Percutaneous coronary intervention in a patient with single coronary artery
by: T.K. Mishra, et al.
Published: (2014-05-01)

Percutaneous coronary intervention in a rare variety of single coronary artery
by: Srinivas C. Budanur, et al.
Published: (2015-12-01)

Prasugrel-related hepatotoxicity
by: Zeki Dogan, et al.
Published: (2022-10-01)

Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a systematic review and economic evaluation
by: Y Dundar, et al.
Published: (2007-01-01)

Management of spontaneous coronary artery dissection in the primary percutaneous coronary intervention era.
by: Adlam, D, et al.
Published: (2010)

The Significance of Coronary Artery Calcification for Percutaneous Coronary Interventions
by: Paweł Lis, et al.
Published: (2024-02-01)